Cancer Pharmaceutical-economics examines the economic aspects of cancer treatments, including the costs, benefits, and outcomes associated with various therapies. It involves assessing the value and cost-effectiveness of cancer drugs, considering factors such as survival rates, quality of life, and healthcare resource utilisation.
Delve into the complex world of cancer drug pricing and its impact on patients and healthcare systems with Associate Professor Nathan Cherny of Shaare Zedek Medical Center in Jerusalem, Israel.
A/Prof Cherny will provide a comprehensive framework to explore whether current drug pricing is fair or exploitative.
This session will cover:
Note: this session has been pre-recorded due to the international speaker's availability.
Associate Professor Nathan Cherny is an Australian-born and trained medical oncologist and palliative care physician who has been working at the Shaare Zedek Medical Center in Jerusalem since 1994. He has an active practice in general oncology and oncologic palliative care. A/Prof Cherny is currently the Chair of the ESMO Magnitude of Clinical Benefit Working Group, former chair of the Palliative Care Working Group and current member of the ESMO guidelines steering committee and cancer medicine policy working group.
